Fourteen studies involving a total of 567 COPD patients with PH were included in this systematic review to assess the clinical effectiveness of drugs targeting the NO-sGC-cGMP pathway, namely, sildenafil (Alkhayat and Eid, 2016; Li et al., 2021; Alp et al., 2006; Holverda et al., 2008; Vitulo et al., 2017; Karakitsos et al., 2013; Shrestha et al., 2017; Sharif-Kashani et al., 2014; Blanco et al., 2010; Blanco et al., 2013), riociguat (Ghofrani et al., 2015; Pichl et al., 2019), tadalafil (Maron et al., 2022), and inhaled NO (Vonbank et al., 2003). The gene discussed is SGCB; the disease is chronic obstructive pulmonary disease.